Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

New York

CNS medication trials in New York

130 CNS medication studies are recruiting participants at sites in 32 cities across New York as of November 17, 2026, according to ClinicalTrials.gov.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every New York city with a recruiting study

By research area: Depression (46), Schizophrenia (19), Parkinson's Disease (18), Migraine (17), Multiple Sclerosis (12), Epilepsy (9), ADHD (5), Bipolar Disorder (4).

New York (84), Staten Island (17), Amherst (14), The Bronx (14), Brooklyn (13), Cedarhurst (10), Commack (7), Rochester (7), Mineola (5), Mount Kisco (5), Syracuse (5), Buffalo (4), East Syracuse (4), Albany (3), Glen Oaks (3), Great Neck (2), Manhasset (2), Manlius (2), Stony Brook (2), Williamsville (2), Kingston (1), Lake Success (1), Lewiston (1), Manhattan (1), Middletown (1), New Windsor (1), Nyack (1), Orangeburg (1), Port Jefferson Station (1), Valhalla (1), White Plains (1), Woodmere (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Depression: recently updated in New York

Basic details from each study's public record (the 12 most recently updated of 130). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Recruiting in
    Brooklyn · New York
    Registry record
    NCT07226661 · updated
  2. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Recruiting in
    New York · The Bronx
    Registry record
    NCT06793397 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in New York on ClinicalTrials.gov.

Parkinson's disease: recently updated in New York

  1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Buffalo · East Syracuse · New York · and 3 more U.S. locations
    Registry record
    NCT06623422 · updated
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Mineola · New York
    Registry record
    NCT06841354 · updated
  3. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Mineola · New York
    Registry record
    NCT06952504 · updated
  4. A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Mineola · New York
    Registry record
    NCT07216703 · updated
  5. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Recruiting in
    New York
    Registry record
    NCT06989112 · updated
  6. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    East Syracuse
    Registry record
    NCT06469944 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in New York on ClinicalTrials.gov.

Multiple sclerosis (MS): recently updated in New York

  1. Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment

    • Phase 1
    • Ages 18 to 75
    • All sexes
    Sponsor
    Kite, A Gilead Company
    Recruiting in
    New York
    Registry record
    NCT07304154 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in New York on ClinicalTrials.gov.

Epilepsy: recently updated in New York

  1. Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

    • Phase 4
    • Ages 18 and older
    • All sexes
    Sponsor
    VA Office of Research and Development
    Recruiting in
    New York
    Registry record
    NCT04419272 · updated
  2. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Recruiting in
    New York · The Bronx
    Registry record
    NCT07563881 · updated
  3. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Recruiting in
    New York
    Registry record
    NCT07594119 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in New York on ClinicalTrials.gov.

Ask about studies in New York

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call